Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting
Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting
Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting
Submitted by
admin
on June 5, 2011 - 10:03am
Source:
Yahoo/BusinessWire
News Tags:
Incyte
ruxolitinib
INC424
myelofibrosis
Headline:
Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting
Do Not Allow Advertisers to Use My Personal information
